Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-02
2011-08-02
Audet, Maury (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S326000, C424S001690
Reexamination Certificate
active
07989415
ABSTRACT:
Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
REFERENCES:
patent: 4444887 (1984-04-01), Hoffmann
patent: 4716111 (1987-12-01), Osband et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5436169 (1995-07-01), Iovanna et al.
patent: 5516637 (1996-05-01), Huang et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5698426 (1997-12-01), Huse
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5750753 (1998-05-01), Kimae et al.
patent: 5766886 (1998-06-01), Studnicka et al.
patent: 5780225 (1998-07-01), Wigler et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5821047 (1998-10-01), Garrard et al.
patent: 5834590 (1998-11-01), Vinik et al.
patent: 5840531 (1998-11-01), Vinik et al.
patent: 5959086 (1999-09-01), Iovanna et al.
patent: 5969108 (1999-10-01), McCafferty et al.
patent: 6311415 (2001-11-01), Lind
patent: 6407213 (2002-06-01), Carter et al.
patent: 6946151 (2005-09-01), Chatterji
patent: RE39062 (2006-04-01), Vinik et al.
patent: RE39299 (2006-09-01), Vinik et al.
patent: 7166439 (2007-01-01), Vinik et al.
patent: 7393919 (2008-07-01), Levetan et al.
patent: 7714103 (2010-05-01), Levetan et al.
patent: 2003/0035803 (2003-02-01), McMichael
patent: 2003/0212000 (2003-11-01), Van Antwerp
patent: 2004/0132644 (2004-07-01), Vinik et al.
patent: 2005/0084449 (2005-04-01), Landes et al.
patent: 2006/0198839 (2006-09-01), Levetan
patent: 2007/0087971 (2007-04-01), Levetan et al.
patent: 2007/0184504 (2007-08-01), Vinik et al.
patent: 2008/0300190 (2008-12-01), Levetan et al.
patent: 2009/0142338 (2009-06-01), Levetan
patent: 0303233 (1989-02-01), None
patent: 239400 (1994-08-01), None
patent: 1329458 (2000-12-01), None
patent: 592106 (2004-11-01), None
patent: 519596 (2005-02-01), None
patent: WO 90/02809 (1990-03-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 91/10737 (1991-07-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 91/16428 (1991-10-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 92/18619 (1992-10-01), None
patent: WO 92/22324 (1992-12-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 93/17105 (1993-09-01), None
patent: WO 95/15982 (1995-06-01), None
patent: WO 95/20401 (1995-08-01), None
patent: WO 96/19236 (1996-06-01), None
patent: WO 96/26215 (1996-08-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 97/13844 (1997-04-01), None
patent: WO 98/16654 (1998-04-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/46645 (1998-10-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 03/033808 (2003-04-01), None
patent: WO 03/105897 (2003-12-01), None
patent: WO 2006/096565 (2006-09-01), None
patent: WO 2006/128083 (2006-11-01), None
Agardh, et al., Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes,J. Diabetes Complications(2005) 19(4):238-246.
Ames, et al., Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins,J. Immunol. Methods(1995) 184:177-186.
Andersen, et al., Oral Glucose Augmentation of Insulin Secretion,J. Clin. Invest. (1978) 62:152-161.
Atherton, et al., Solid Phase Peptide Synthesis: A Practical Approach,IRL Press, Oxford (1989) (TOC).
Ausubel, et al., Current Protocols in Molecular Biology, vol. 1, John Wiley & Sons (2008) (TOC).
Ausubel, et al., Short Protocols in Molecular Biology, Current Protocols in Molecular Biology, 2nd ed., John Wiley & Sons (1992) (TOC).
Baca, et al., Antibody Humanization Using Monovalent Phage Display,J. Biol. Chem. (1997) 272(16):10678-10684.
Bach, et al., Tolerance to Islet Autoantigens in Type 1 Diabetes,Ann. Rev. Immun. (2001) 19:131-161.
Better, et al.,Escherichia coliSecretion of an Active Chimeric Antibody Fragment,Science(1988) 240:1041-1043.
Bitter, et al., Expression and Secretion Vectors for Yeast,Methods in Enzymol. (1987) 153:516-544.
Bodanszky Peptide Chemistry, A Practical Textbook, 2nd ed., Springer-Verlag, Berlin (1993) (TOC).
Bonner-Weir, et al., The pancreatic ductal epithelium serves as a potential pool of progenitor cells,Pediatric Diabetes(2004) 5 (Suppl 2):16-22.
Brinkmann, et al., Phage display of disulfide-stabilized Fv fragments,J. Immunol. Methods(1995) 182:41-50.
Burton, et al., Human Antibodies from Combinatorial Libraries,Advances in Immunology(1994) 57:191-280.
Buse, et al., Amylin replacement with pramlinlide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy,Clin. Diab. (2002) 20:137-144.
Caldas, et al., Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen,Protein Eng. (2000) 13(5):353-360.
Casteels, et al., Prevention of Type I Diabetes in Nonobese Diabetic Mice by Late Intervention with Nonhypercalcemic Analogs of 1,25-Dihydroxyvitamin D3 in Combination with a Short Induction Course of Cyclosporin A,Endocrionology(1998) 139(1):95-102.
Cockett, et al., High Level Expression of Tissue Inhibitor of Metalloproteinases in Chinese Hamster Ovary Cells Using Glutamine Synthetase Gene Amplification,Bio/Technology(1990) 8:662-667.
Colbere-Garapin, et al., A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells,J. Mol. Biol. (1981) 150:1-14.
Couto, et al., Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus and in Vivo and in Vitro Characterization,Cancer Res. (1995,) 55(8):1717-1722.
Couto, et al., Designing Human Consensus Antibodies with Minimal Positional Templates,Cancer Res. (1995) 55(23 Suppl):5973s-5977s.
Creutzfeldt, The Incretin Concept Today,Diabetologia(1979) 16:75-85.
Creutzfeldt, et al., Inhibition of Gastric Inhibitory Polypeptide (GIP) Release by Insulin and Glucose in Juvenile Diabetes,Diabetes(1980) 29(2):140-145.
Creutzfeldt, et al., New developments in the incretin concept,Diabetologia(1985) 28:565-573.
Davis, et al., The effects of HDV-insulin on carbohydrate metabolism in Type 1 diabetic patients,J. Diabetes Comp. (2001) 15(5):227-233.
Delovitch, et al., The Nonobese Diabetic Mouse as a Model of Autoimmune Diabetes: Immune Dysregulation Gets the NOD,Immunity(1997) 7:727-738.
Dicesar, et al., Vitamin D Deficiency is More Common in Type 2 Than in Type 1 Diabetes,Diabetes Care(Jan. 2006) 29(1):174.
Dupre, et al., Exendin-4 Normalized Postcibal Glycemic Excursions in Type 1 Diabetes,J. Clin. Endocrin. Metab. (2004) 89(7):3469-3473.
Dupre, et al., Stimulation of Insulin Secretion by Gastric Inhibitory Polypeptide in Man,J. Clin. Endocrin. Metab. (1973) 37:826-828.
Ebert, et al., Gastric Inhibitory Polypeptide,Clin. in Gastroenterology(1980) 9(3):679-698.
Edwards, et al., Glucagon-Like Peptide 1 Has a Physiological Role in the Control of Postprandial Glucose in Humans,Diabetes(1999) 48:86-93.
Elahi, et al., Pancreatic α- and β-cell responses to GIP infusion in normal man,Am. J. Physiol. (1979) 237:E185-E191.
Elahi, et al., The insulinotropic actions of glucose-dependent insulinotropic polypeptide (IP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects,Regulatory Peptide(1994) 51(1):63-74.
Foecking, e
Levetan Claresa S.
Upham Loraine V.
Audet Maury
CureDM Group Holdings, LLC
Pepper Hamilton LLP
LandOfFree
Peptides, derivatives and analogs thereof, and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides, derivatives and analogs thereof, and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides, derivatives and analogs thereof, and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2740682